jnj-75220795
Nucleic acidexperimental
Clinical trial activity
2 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Apr 29, 2021 (NCT04844450)
Timeline
2020s
- Jan 1, 2021
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Hepatocyte growth factor receptorANTISENSE INHIBITOR
MET antisense inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05039710 | Phase 1 | Nov 10, 2021 | Janssen Pharmaceutica NV |
| NCT04844450 | Phase 1 | Apr 29, 2021 | Janssen Pharmaceutica NV |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Janssen Pharmaceutica NV | For profit | 2 | 2 | 1 | 2021 |
1 organizations
Page 1 / 1